Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Filament Health Corp (OP: FLHLF )

0.0684 +0.0066 (+10.68%)
Streaming Delayed Price Updated: 3:09 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,000
Open 0.0684
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0618
Today's Range 0.0684 - 0.0684
52wk Range 0.0342 - 0.1611
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UCSF Clinical Trial Shows Promising Results For Naturally-Sourced Psilocybin And Psilocin
A Phase 1 clinical trial led by the University of California San Francisco (UCSF) assessing research partner Filament Health Corp.’s (OTCQB: FLHLF) botanical psychedelic drug candidates has shown... 
Via Benzinga
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga

Performance

YTD
+36.80%
+36.80%
1 Month
-2.29%
-2.29%
3 Month
+8.40%
+8.40%
6 Month
+30.29%
+30.29%
1 Year
-45.02%
-45.02%

More News

Read More
African Iboga Root Heads To Canadian Company Developing Natural Drugs To Help Treat Addictions
Via Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Via Benzinga
Filament Health's Q1 2023 Financial Results, Material Uncertainty On The Horizon
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Via Benzinga
Two Psychedelics Companies Collaborate To Provide Clinical-Grade MDMA Capsules For Authorized Patients And Studies
Via Benzinga
Filament Health: 2022 Financials And Operational Highlights From Creator Of The Ayahuasca Pill
Via Benzinga
Psychedelic Research Expands In Australia With Palliative Care Partnership & New MDMA Analog Portfolio
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Via Benzinga
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
Via Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Via Benzinga
[Video] Revolutionizing Mental Health: Filament Health CEO Discusses The Future Of Psychedelic Medicine
Via Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Via Benzinga
Supply Partnerships: Filament's Psilocybin Trial In Canada, PharmAla's MDMA Program In Australia
Via Benzinga
EXCLUSIVE: Defining 'Natural' Psychedelics, State Regulations & Ayahuasca's Benefits
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Via Benzinga
Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences
Via ACCESSWIRE
Psychiatry And Business Collaborate: European Psychedelics Trial Tackles Alcohol Addiction
Via Benzinga
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Via Benzinga
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses
Via ACCESSWIRE
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Via Benzinga
EXCLUSIVE: The Psychedelics Debate Is 'Raging' As Filament Debuts Ayahuasca Pill
Via Benzinga
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Psychedelics Company Filament Signs Licensing Deal With Psyence In US, UK And EU
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.